Medication info

BMBSan (Sodium Bicarbonate)

Prescription medication
Ingredient · strength
Sodium Bicarbonate›1g / 1g
Manufacturer / importer
Wonkwang Pharmaceutical Co., Ltd.
Appearance
White crystalline powder in a white polyethylene bag
Packaging
16.8 kilograms/box - 16.8 kilograms/box[(8.4 kilograms/PE bag × 2)]
Approval status
Active

MFDS item code 202303350 · Notified 2023.12.15

Summary

Main use
Treatment of renal failure and detoxification of toxic substances through preparation of a hemodialysis solution
Who uses it
Adults
Adult dosage
1. When using the specified acetate-containing dialysate (Solution A), this product can prepare approximately 180L of bicarbonate-type hemodialysis dialysate containing 38mEq/L of HCO3-. 2. Use as dialysate for hemodialysis performed with a bicarbonate-type dialysate delivery system, using a dilution ratio of 1 part acetate-containing dialysate (Solution A) to 34 parts (this product + purified water). 3. The mixing ratio for preparing dialysate for one treatment per patient (based on 6 hours) is as follows. Solution A : (sodium bicarbonate + purified water) = 5L : (650g + 170L) 4. For routine bicarbonate-type hemodialysis, use a dialysate delivery system and adjust the electrolyte concentrations as follows. Na+ : 140mEq/L HCO3- : 34mEq/L

Ingredients

Manufacturer
Wonkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of renal failure and detoxification of toxic substances through preparation of a hemodialysis solution

View approved original text

This medication is used to prepare the dialysate for hemodialysis using sodium bicarbonate in patients with acute and chronic renal failure. It is also used during hemodialysis for the detoxification of patients with toxic substance poisoning. In summary, this drug is used to prepare dialysate for hemodialysis for the elimination of waste products from the body of renal failure patients and for detoxification of toxic substances.

Dosage and Administration

Adult dosage

1. When using the specified acetate-containing dialysate (Solution A), this product can prepare approximately 180L of bicarbonate-type hemodialysis dialysate containing 38mEq/L of HCO3-. 2. Use as dialysate for hemodialysis performed with a bicarbonate-type dialysate delivery system, using a dilution ratio of 1 part acetate-containing dialysate (Solution A) to 34 parts (this product + purified water). 3. The mixing ratio for preparing dialysate for one treatment per patient (based on 6 hours) is as follows. Solution A : (sodium bicarbonate + purified water) = 5L : (650g + 170L) 4. For routine bicarbonate-type hemodialysis, use a dialysate delivery system and adjust the electrolyte concentrations as follows. Na+ : 140mEq/L HCO3- : 34mEq/L

Precautions

This drug should not be used in patients with low blood pressure and rapid heart rate. It should also be avoided in patients with pulmonary edema or abnormalities in the electrocardiogram, as well as in patients with high potassium levels or issues with blood clotting. Care should be taken when using in patients with severely impaired liver function or metabolic disorders due to diabetes. Particularly patients taking medications that affect the heart may experience side effects due to this drug, so caution is necessary. Patients with high levels of calcium and phosphorus in the blood should also exercise caution when using this medication prior to dialysis. Care must be taken in cases of poor nutritional status or in diabetic patients who face dietary restrictions or use hypoglycemic agents, as there is a risk of hypoglycemia. This drug can cause side effects such as hypoglycemia or hypercalcemia during dialysis, so appropriate treatment is needed in case symptoms occur. Bone disorders such as osteoporosis or osteomalacia may develop, so regular examinations and vitamin D supplementation are recommended. Symptoms associated with dialysis disequilibrium syndrome such as headaches, nausea, and seizures may occur, and measures such as adjusting the dialysis speed are needed if symptoms arise. Circulatory problems may cause a sudden drop in blood pressure or symptoms of shock; in such cases, dialysis should be stopped immediately, and appropriate treatment should be provided. This drug is used in the hemodialysis of chronic renal failure patients, particularly when there is severe metabolic acidosis or hypotension during dialysis. For diabetic patients with poor glycemic control, using this drug, which does not contain glucose, can be beneficial. During treatment, it is important to regularly conduct blood tests to check the status of electrolytes and blood glucose. Pregnant women or women of childbearing potential should use this drug cautiously as its safety may not be established, under the guidance of a physician. The safety in children has not been fully established, thus special care is needed when administering to pediatric patients. Elderly patients may develop bone disorders when using this drug long-term, so regular examinations and vitamin D supplementation are necessary. The diluent for dialysis should be clean and subjected to appropriate purification processes. Careful monitoring of the dialysis membrane for damage and bleeding tendency is also essential. This drug may precipitate when mixed with other dialysis electrolyte solutions, so it should not be mixed directly and should be diluted according to prescribed methods. If the concentration of the dialysate is too high or low, symptoms such as headaches, blood pressure changes, and numbness may occur, so concentrations must be adjusted accurately. Before use, it is safe to verify the electrolyte concentration and pH of the dialysate. The solution should be used immediately after preparation, and care should be taken to prevent the formation of insoluble substances during storage. This drug is not to be used for injection or peritoneal dialysis, and attention should be paid to maintaining the serum osmotic pressure and balance in dialysis patients. It is advisable to match the temperature to body temperature when using.

Side effects

  • Hypoglycemia
  • hypercalcemia
  • osteoporosis
  • osteomalacia
  • fibrous osteitis
  • ectopic calcification
  • headache
  • nausea
  • vomiting
  • convulsions
Show 13 more
  • altered consciousness
  • discomfort
  • lethargy
  • hypotension
  • shock symptoms
  • increased blood pressure
  • headache
  • palpitations
  • consciousness disturbance
  • limb paralysis sensation
  • generalized malaise
  • chest discomfort
  • rapid decrease in blood pressure

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to prevent air and moisture ingress. It should also be kept away from excessively hot or cold environments, ideally stored at room temperature between 1 and 30 degrees.

Appearance and packaging

Appearance

White crystalline powder in a white polyethylene bag

Package unit

16.8 kilograms/box - 16.8 kilograms/box[(8.4 kilograms/PE bag × 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.